Log In
BCIQ
Print this Print this
 

sparsentan (RE-021)

  Manage Alerts
Collapse Summary General Information
Company Ligand Pharmaceuticals Inc.
DescriptionSmall molecule dual angiotensin and endothelin receptor antagonist
Molecular Target Angiotensin receptor ; Endothelin receptor
Mechanism of ActionEndothelin receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationNephropathy
Indication DetailsTreat focal segmental glomerulosclerosis (FSGS)
Regulatory Designation U.S. - Orphan Drug (Treat focal segmental glomerulosclerosis (FSGS));
EU - Orphan Drug (Treat focal segmental glomerulosclerosis (FSGS))
PartnerRetrophin Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/18/2012

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today